Industry Outlook

The global blood-brain barrier market projected to reach US$ 5,704.2 Mn by 2026 from US$ 696.4 Mn in 2017, growing at a CAGR of 25.0% during the forecast period from 2018 to 2026. The blood-brain barrier (BBB) prevents free flow of elements from circulatory system to the cerebrospinal fluid (CSF) or brain with specific exchange of elements regulated by blood-brain barrier and blood-CSF barrier. They key components of BBB are endothelial cells, capillary basement membrane, astrocytes, and pericytes. Physiologically water, CO2, oxygen and lipid soluble molecules are capable of travelling across the blood-brain barrier; adenosine triphosphate (ATP) produced by mitochondria carries out the active transport.   

Alzheimer’s & Parkinson Diseases are the most prevalent diseases assisting the growth of blood-brain barrier market

In year 2016, epilepsy, Alzheimer’s and Parkinson’s disease dominated the market with more than 50% of the market share collectively owing to increasing prevalence of these diseases, introduction of novel diagnostic technology for these diseases, and rising awareness programs organized by governmental and non-governmental organizations is assisting the growth of diagnostic market of these diseases. In addition, increasing geriatric population and rising prevalence of lifestyle-specific CNS disorders are assisting the growth of global demand for blood-brain barrier technologies. According to Sanofi S.A., Epilepsy is the most common neurological disorder affecting about 20-50 million people worldwide. The disease is more frequent in children than in adults, the highest incidence being in the neonatal period of life, and then declining markedly before rising in the old age. During the forecast period 2018 to 2026, Asia Pacific identified as the fastest growing blood-brain barrier market due to major driving factors such as mounting prevalence and incidence of diseases affecting central nervous system in geriatric population.

Technological advancements and rising accessibility to modern technology in developing countries of Asia Pacific is driving the market growth

In base year 2016, North America accounted for the largest share in global blood-brain barrier market due to key driving factors such as rising prevalence of neurological diseases, supportive reimbursement policies, high awareness related to early neurological disease diagnosis and treatment, and incessant developments in the field of blood-brain barrier technologies research and development. According to a research report, an estimated 5.4 million Americans have Alzheimer’s disease and today someone in America develops Alzheimer’s disease every 68 seconds. By 2050, it is expected that one new case of Alzheimer’s disease will be diagnosed for every 33 seconds, or nearly a million new cases per year, and Alzheimer’s disease global prevalence is projected to reach 16 million. During the forecast period 2018 to 2026, Asia Pacific was identified as the fastest growing BBB market due to key driving factors such as increasing prevalence of CNS disorders, rapidly evolving healthcare infrastructure, and rising awareness associated with neurological diseases. Thus, increasing awareness is fueling the rate of diagnosis, and mounting accessibility of patients to modern treatment solutions especially observed in developing countries of this region.

Blood-brain barrier technologies are developing rapidly and its pipeline is very strong

The blood-brain barrier comprises technologies as follows:

• SonoCloud – (Phase I/IIa)
• MRI-guided laser ablation + Doxorubicin + Etoposide + Dynamic contrast-enhanced (DCE) MRI – (Phase I)
• P03277 + Gadobenate dimeglumine + MRI – (Phase II Completed)
• Carboplatin + Mannitol + Melphalan + Sodium Thiosulfate – (Phase I/II)
• Intra-arterial Cerebral Infusion of Trastuzumab (Phase I)
• 25% Mannitol + Low-dose Intra-arterial Bevacizumab – (Phase II)

The most promising products in this list are SonoCloud, and P03277 + Gadobenate dimeglumine, SonoCloud is owned by CARTHERA, and Guerbet owns P03277 + Gadobenate dimeglumine.

This report further describes the major qualitative assessment factors including key market trends, market drivers & restraints, to assist in better understanding of global blood-brain barrier market. Furthermore, the key players analyzed graphically based on their product offering, market strategies and business strength. The report also provides attractive investment proposition based on the extensive geographical research carried out based on PESTEL analysis. Key players profiled in the report include Allon Therapeutics, Inc., Angiochem Inc., Armagen Technologies, Inc., BrainsGate, Bristol-Myers Squibb, BiOasis Technologies, Inc., Sanofi Genzyme, CarThera, Cephalon Inc., F. Hoffman La-Roche, Janssen Pharmaceutica NV, and others.

Historical & Forecast Period

This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Blood-Brain Barrier market are as follows:

• Research and development budgets of manufacturers and government spending
• Revenues of key companies in the market segment
• Number of end users and consumption volume, price and value.
• Geographical revenues generate by countries considered in the report
• Micro and macro environment factors that are currently influencing the Blood-Brain Barrier market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Key questions answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of Blood-Brain Barrier market?
• What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2032.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Blood-Brain Barrier market?
• Which is the largest regional market for Blood-Brain Barrier market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Blood-Brain Barrier market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Blood-Brain Barrier market worldwide?